| Bioactivity | Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2]. |
| Target | Complement protein C5a |
| Invitro | Olendalizumab 可用作生物素化捕获试剂，在 Bioaffy wash 1 中的工作浓度为 100 μg/mL，同时 AlexaFluor 标记的抗 C5a 克隆 2942 在 Rexxip F 中的工作浓度为 4 μg/mL[1]。补体系统的成员，如 C3、C5a、C5b-9，包括受体，如 C3aR 和 C5aR，介导病毒感染后的肺损伤。 此外，C5/C5a 更是冠状病毒引起的肺损伤中的非沉默补体。Olendalizumab 是有效的 C5a 抑制剂[2]。 |
| Name | Olendalizumab |
| CAS | 2210314-30-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20(6):106. [2]. Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21. |